Press Releases

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. SAN CARLOS and EMERYVILLE, Calif. — July 11, 2025 — Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch […]

EMERYVILLE, Calif. — June 3, 2025 — Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO), today announced the NMU-Symphony™ system, the second generation of its Nutcracker® Manufacturing Unit (NMU). This milestone is accompanied by an expansion of the production capacity of its Good Manufacturing Practice (GMP) ready facility, in Emeryville, CA. NMU-Symphony™ […]

EMERYVILLE, Calif. — May 1, 2025 — Nutcracker Therapeutics, Inc., a contract, research,development and manufacturing organization (CRDMO) with a next ​generation RNA precisionmanufacturing platform, today announced its participation in two premier industry events thisMay: the 3rd mRNA Process Development & Manufacturing Summit Europe in Berlin and the2025 TIDES USA Conference in San Diego. The company […]

EMERYVILLE, Calif. — March 26, 2025 — Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ​generation RNA precision manufacturing platform, announced today that Chief Executive Officer (CEO) Igor Khandros, Ph.D., is retiring from the company’s top leadership position. Cynthia Collins, a member of the company’s board of directors, has […]

EMERYVILLE, Calif., November 25, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced its participation in the 2024 Personalized Cancer Vaccine Summit, which includes a talk by Chief Scientific Officer Sam Deutsch, Ph.D. The event, which is taking place from December 3-5 in […]

EMERYVILLE, Calif., November 12, 2024 — Nutcracker Therapeutics, Inc., a pioneering biotechnology company dedicated to enabling transformative RNA therapies through its proprietary technology platform, today announced its new contract research, development, and manufacturing organization (CRDMO) capabilities, which will provide next-generation design and biomanufacturing solutions for RNA drug developers. Nutcracker Therapeutics’ manufacturing solutions can be scaled […]

EMERYVILLE, Calif., August 7, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell® platform of peptoid-based mRNA delivery vehicles. The paper, published in ACS Nano, outlines the design […]

EMERYVILLE, Calif., June 5, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Monoclonal antibody immunotherapies can […]

EMERYVILLE, Calif., May 15, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from May 31 to June 4. […]